Endogenous Cushing’s Syndrome Therapeutics Market

Endogenous Cushing’s Syndrome Therapeutics Market

  • HC-6350
  • 4.9 Rating
  • 219 Pages
  • Upcoming
  • 78 Reviews
  • Docx PDF Excel PPT
raksha

Author :

Raksha Sharma

Vineet

Fact-checked by :

Vineet Pandey

Vishal

Editor :

Vishal Golekar

Endogenous Cushing’s Syndrome Therapeutics Market Outlook 2032 

The global endogenous Cushing’s syndrome therapeutics market size was USD 127.7 Million in 2023 and is likely to reach USD 291.5 Million by 2032, expanding at a CAGR of 9.6% during 2024–2032. The market growth is attributed to the increasing prevalence of Cushing’s disease.

Endogenous Cushing's syndrome arises when your body produces too much of the hormone cortisol. This excess disrupts various bodily functions, leading to a range of symptoms. According to the National Center for Biotechnology Information, endogenous Cushing’s syndrome accounts for 60% to 80% of all cases of Cushing’s syndrome globally.

Cushing's syndrome is managed with established therapies such as steroidogenesis inhibitors, adrenolytic agents, and glucocorticoid receptor antagonists. These medications suppress cortisol production in the adrenal glands and offer symptom relief. However, the market is witnessing the development of novel, targeted therapies with less side effects, offering personalized treatment options.

Several late-stage pipeline therapies are in development, with potential approvals that expected in the coming years. These therapies target different aspects of the disease pathway, offering promise for improved efficacy and less side effects.

 Endogenous Cushing’s Syndrome Therapeutics Market Outlook

Impact of Artificial Intelligence (AI) in Endogenous Cushing’s Syndrome Therapeutics Market

Artificial Intelligence (AI) has the potential to significantly impact the Cushing's syndrome therapeutics market by enhancing drug discovery, identifying novel drug targets, virtual drug screening, and predictive modeling. AI algorithms analyze vast datasets, virtually screen millions of potential drugs, and prioritize promising candidates for clinical trials.

AI algorithms improve diagnosis and treatment selection by analyzing medical images, recommending personalized treatments based on individual needs, and strategizing risk based on patient data, potentially reducing complications from Cushing's syndrome or potential side effects.

Endogenous Cushing’s Syndrome Therapeutics Market Dynamics

 Endogenous Cushing’s Syndrome Therapeutics Market Dynamics


Major Drivers

Increasing awareness of Cushing’s syndrome and development of target therapies is expected to drive the global market. The development of targeted therapies that address specific aspects of the disease pathway, such as steroidogenesis inhibitors and cortisol receptor antagonists, offers personalized and potentially effective treatment options.

Existing Restraints

Limited options of medicines and side effects is expected to restrain the market during the forecast period. Existing therapies have significant side effects, and there is a lack of curative options. With only a handful of treatment options available, the market is restricted to patients who can tolerate and benefit from those specific medications. This limits the overall patient pool that can be treated, thus hindering the market.

Emerging Opportunities

Increasing focus on targeted therapies and biomarker identification for different subtypes of Cushing’s syndrome is expected to provide high opportunities in the market. Identifying biomarkers for different Cushing's syndrome subtypes allows for targeted treatment approaches based on individual patient needs. Development of accurate and non-invasive diagnostic tests is expected to facilitate early detection and improve patient outcomes.

Scope of the Endogenous Cushing’s Syndrome Therapeutics Market Report

The market report includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.

Attributes

Details

Report Title

Endogenous Cushing’s Syndrome Therapeutics Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast

Base Year

2023

Historic Data

2017–2022

Forecast Period

2024–2032

Segmentation

Drug Class (11-Beta-Hydroxylase Inhibitor and Adrenal Steroid Inhibitors), and Distribution Channel (Hospitals Pharmacies, Retail Pharmacies, and Online Pharmacies)

Regional Scope

Asia Pacific, North America, Latin America, Europe, and Middle East & Africa

Report Coverage

Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, Market Trends, and Revenue Forecast

Key Players Covered in the Report

AbbVie Inc.; AstraZeneca Plc; Bayer AG; Bristol-Myers Squibb Company; F. Hoffmann-La Roche Ltd.; GlaxoSmithKline Plc; Merck & Co. Inc.; Mylan N.V.; Novartis AG; Pfizer Inc.; Sanofi S.A.; and Teva Pharmaceutical Industries Ltd.


Endogenous Cushing’s Syndrome Therapeutics Market Segment Insights

Drug Class Segment Analysis

Based on drug class, the market is divided into 11-Beta-Hydroxylase inhibitor and adrenal steroid inhibitors. The adrenal steroid inhibitors segment is expected to expand at a significant CAGR during the projection period, as it is the most common option for treatment. Moreover, the affordability of these drugs with sufficient efficacy is expected to fuel the segment during the forecast period. The wide availability of treatment and in many countries is increasing the accessibility of endogenous Cushing’s syndrome therapeutics and driving the segment.

The 11-Beta-Hydroxylase inhibitor segment is expected to hold a significant share of the market in the coming years, as 11β-Hydroxylase (CYP11B1) is considered as an attractive target for treating the diseases. Furthermore, 11β-Hydroxylase is a key enzyme responsible for the last step in cortisol biosynthesis, thus driving the segment. Inhibitors such as, steroidogenesis blockers are CYP11B1 inhibitors are frequently getting utilized. Recent advancements in reducing the side effects of these drugs are overcoming the limitations and hence, is anticipated to boost the segment during the forecast period.

 Endogenous Cushing’s Syndrome Therapeutics Market Drug class

Distribution Channel Segment Analysis

On the basis of distribution channel, the global market is segregated into hospitals pharmacy, retail pharmacy, online pharmacy. The hospital pharmacy segment is anticipated to expand at a considerable CAGR in the coming years due to the wide availability of specialized drug. Hospital pharmacies are well-equipped and has skilled staffs, providing proper explanation of dosage and side effects are expected to boost the segment.
 
The retail pharmacies segment is expected to expand at a significant CAGR during the forecast period. The ease in availability for varied medications and treatment options nearby is increasing the convenience and accessibility. Furthermore, the wide range of services is boosting the segment. Many retail pharmacies offer additional services beyond dispensing medications. This includes vaccinations, medication reviews, basic health screenings, and over-the-counter medication sales.

 Endogenous Cushing’s Syndrome Therapeutics Market Distribution Channel

Regional Analysis

In terms of region, the global endogenous Cushing’s syndrome therapeutics market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. North America is expected to dominate the market during the forecast period owing to the high prevalence of endogenous Cushing’s disease. Additionally, the advanced healthcare system and well-equipped infrastructure is propelling the regional market. According to the National Organization for Rare Disorders, the incidence rate of endogenous Cushing’s syndrome is approximately 13 per million people annually in the US. Furthermore, many government and private organizations are taking initiative to get sponsors for the clinical trials of endogenous Cushing’s syndrome drug.

  • In September 2023, Food and Drug Administration, in the US, released a draft entitled Endogenous Cushing’s Syndrome: Developing Drugs for Treatment for industrial guidance and provide recommendations to sponsor for clinical trials of drugs intended for the treatment of adults with endogenous Cushing’s syndrome for whom surgery is not an option or has not been curative.

Asia Pacific is expected to hold a large share during the forecast period due to increasing awareness and diagnosis for endogenous Cushing's syndrome among healthcare professionals and the general population in Asia Pacific. Improved diagnostic techniques and increased screening efforts contribute to early detection and diagnosis of the condition, leading to a large patient pool seeking treatment. Moreover, rising healthcare expenditure is expected to boost the market in the region. Many countries in Asia Pacific are experiencing economic growth, leading to increased healthcare spending. This results in improved access to healthcare services, including diagnosis and treatment for rare conditions like Cushing's syndrome.

 Endogenous Cushing’s Syndrome Therapeutics Market Region

Segments

The endogenous Cushing’s syndrome therapeutics market has been segmented on the basis of

Drug Class

  • 11-Beta-Hydroxylase Inhibitor 
  • Adrenal Steroid Inhibitors

Distribution Channel

  • Hospitals Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Region

  • Asia Pacific
  • North America
  • Latin America
  • Europe
  • Middle East & Africa

Key Players

  • AbbVie Inc.
  • AstraZeneca Plc
  • Bayer AG
  • Bristol-Myers Squibb Company
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline Plc
  • Merck & Co. Inc.
  • Mylan N.V.
  • Novartis AG
  • Pfizer Inc.
  • Sanofi S.A.
  • Teva Pharmaceutical Industries Ltd.

Competitive Landscape

Key players competing in the global endogenous Cushing’s syndrome therapeutics market are AbbVie Inc.; AstraZeneca Plc; Bayer AG; Bristol-Myers Squibb Company; F. Hoffmann-La Roche Ltd.; GlaxoSmithKline Plc; Merck & Co. Inc.; Mylan N.V.; Novartis AG; Pfizer Inc.; Sanofi S.A.; and Teva Pharmaceutical Industries Ltd.

These companies adopted development strategies including mergers, acquisitions, partnerships, collaboration, product launches, and production expansion to expand their consumer base worldwide. For instance,

  • In January 2023, Xeris Biopharma Holdings Inc. received FDA orphan-drug exclusivity for Recorlev (levoketoconazole) in January 2023, a cortisol synthesis inhibitor and steroidogenesis inhibitor, for treating adult patients with endogenous Cushing's syndrome.

     Endogenous Cushing’s Syndrome Therapeutics Market Key Players

1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Endogenous Cushing’s Syndrome Therapeutics Market Overview
  4.1. Introduction
     4.1.1. Market Taxonomy
     4.1.2. Market Definition
  4.2. Macro-Economic Factors
     4.2.1. Industry Outlook
  4.3. Endogenous Cushing’s Syndrome Therapeutics Market Dynamics
     4.3.1. Market Drivers
     4.3.2. Market Restraints
     4.3.3. Opportunity
     4.3.4. Market Trends
  4.4. Endogenous Cushing’s Syndrome Therapeutics Market - Supply Chain
  4.5. Global Endogenous Cushing’s Syndrome Therapeutics Market Forecast
     4.5.1. Endogenous Cushing’s Syndrome Therapeutics Market Size (US$ Mn) and Y-o-Y Growth
     4.5.2. Endogenous Cushing’s Syndrome Therapeutics Market Size (000’ Units) and Y-o-Y Growth
     4.5.3. Endogenous Cushing’s Syndrome Therapeutics Market Absolute $ Opportunity
5. Global Endogenous Cushing’s Syndrome Therapeutics Market Analysis and Forecast by Region
  5.1. Market Trends
  5.2. Introduction
     5.2.1. Basis Point Share (BPS) Analysis by Region
     5.2.2. Y-o-Y Growth Projections by Region
  5.3. Endogenous Cushing’s Syndrome Therapeutics Market Size and Volume Forecast by Region
     5.3.1. North America
     5.3.2. Latin America
     5.3.3. Europe
     5.3.4. Asia Pacific
     5.3.5. Middle East and Africa (MEA)
  5.4. Absolute $ Opportunity Assessment by Region
  5.5. Market Attractiveness/Growth Potential Analysis by Region
  5.6. Global Endogenous Cushing’s Syndrome Therapeutics Demand Share Forecast, 2019-2026
6. North America Endogenous Cushing’s Syndrome Therapeutics Market Analysis and Forecast
  6.1. Introduction
     6.1.1. Basis Point Share (BPS) Analysis by Country
     6.1.2. Y-o-Y Growth Projections by Country
  6.2. North America Endogenous Cushing’s Syndrome Therapeutics Market Size and Volume Forecast by Country
     6.2.1. U.S.
     6.2.2. Canada
  6.3. Absolute $ Opportunity Assessment by Country
  6.4. Market Attractiveness/Growth Potential Analysis
     6.4.1. By Country
     6.4.2. By Product Type
     6.4.3. By Application
  6.5. North America Endogenous Cushing’s Syndrome Therapeutics Demand Share Forecast, 2019-2026
7. Latin America Endogenous Cushing’s Syndrome Therapeutics Market Analysis and Forecast
  7.1. Introduction
     7.1.1. Basis Point Share (BPS) Analysis by Country
     7.1.2. Y-o-Y Growth Projections by Country
     7.1.3. Latin America Average Pricing Analysis
  7.2. Latin America Endogenous Cushing’s Syndrome Therapeutics Market Size and Volume Forecast by Country
      7.2.1. Brazil
      7.2.2. Mexico
      7.2.3. Rest of Latin America
   7.3. Absolute $ Opportunity Assessment by Country
  7.4. Market Attractiveness/Growth Potential Analysis
     7.4.1. By Country
     7.4.2. By Product Type
     7.4.3. By Application
  7.5. Latin America Endogenous Cushing’s Syndrome Therapeutics Demand Share Forecast, 2019-2026
8. Europe Endogenous Cushing’s Syndrome Therapeutics Market Analysis and Forecast
  8.1. Introduction
     8.1.1. Basis Point Share (BPS) Analysis by Country
     8.1.2. Y-o-Y Growth Projections by Country
     8.1.3. Europe Average Pricing Analysis
  8.2. Europe Endogenous Cushing’s Syndrome Therapeutics Market Size and Volume Forecast by Country
     8.2.1. Germany
     8.2.2. France
     8.2.3. Italy
     8.2.4. U.K.
     8.2.5. Spain
     8.2.6. Russia
     8.2.7. Rest of Europe
  8.3. Absolute $ Opportunity Assessment by Country
  8.4. Market Attractiveness/Growth Potential Analysis
     8.4.1. By Country
     8.4.2. By Product Type
     8.4.3. By Application
  8.5. Europe Endogenous Cushing’s Syndrome Therapeutics Demand Share Forecast, 2019-2026
9. Asia Pacific Endogenous Cushing’s Syndrome Therapeutics Market Analysis and Forecast
  9.1. Introduction
     9.1.1. Basis Point Share (BPS) Analysis by Country
     9.1.2. Y-o-Y Growth Projections by Country
     9.1.3. Asia Pacific Average Pricing Analysis
  9.2. Asia Pacific Endogenous Cushing’s Syndrome Therapeutics Market Size and Volume Forecast by Country
     9.2.1. China
     9.2.2. Japan
     9.2.3. South Korea
     9.2.4. India
     9.2.5. Australia
     9.2.6. Rest of Asia Pacific (APAC)
  9.3. Absolute $ Opportunity Assessment by Country
  9.4. Market Attractiveness/Growth Potential Analysis
     9.4.1. By Country
     9.4.2. By Product Type
     9.4.3. By Application
  9.5. Asia Pacific Endogenous Cushing’s Syndrome Therapeutics Demand Share Forecast, 2019-2026
10. Middle East & Africa Endogenous Cushing’s Syndrome Therapeutics Market Analysis and Forecast
  10.1. Introduction
     10.1.1. Basis Point Share (BPS) Analysis by Country
     10.1.2. Y-o-Y Growth Projections by Country
     10.1.3. Middle East & Africa Average Pricing Analysis
  10.2. Middle East & Africa Endogenous Cushing’s Syndrome Therapeutics Market Size and Volume Forecast by Country
     10.2.1. Saudi Arabia
     10.2.2. South Africa
     10.2.3. UAE
     10.2.4. Rest of Middle East & Africa (MEA)
  10.3. Absolute $ Opportunity Assessment by Country
  10.4. Market Attractiveness/Growth Potential Analysis
     10.4.1. By Country
     10.4.2. By Product Type
     10.4.3. By Application
  10.5. Middle East & Africa Endogenous Cushing’s Syndrome Therapeutics Demand Share Forecast, 2019-2026
11. Competition Landscape
  11.1. Global Endogenous Cushing’s Syndrome Therapeutics Market: Market Share Analysis
  11.2. Endogenous Cushing’s Syndrome Therapeutics Distributors and Customers
  11.3. Endogenous Cushing’s Syndrome Therapeutics Market: Competitive Dashboard
  11.4. Company Profiles (Details: Overview, Financials, Developments, Strategy)

Purchase Premium Report